Search for Clinical Trial Results

Cryopyrin-Associated Periodic Syndromes - 19 Studies Found
Status | Study |
Completed |
Study Name: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Condition: Cryopyrin Associated Periodic Syndrome Date: 2010-03-25 Interventions: Drug: canakinumab (company code: ACZ885D) |
Terminated |
Study Name: HL2351 CAPS Phase II Study Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS) Date: 2016-05-10 Interventions: Drug: HL2351 The dose will be adjusted based on disease activities |
Recruiting |
Study Name: Kineret CAPS Post Authorisation Study Condition: Cryopyrin-Associated Periodic Syndromes Date: 2014-12-01 Interventions: Drug: anakinra (Kineret) Other Name: Kineret |
Completed |
Study Name: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition:
|
Completed |
Study Name: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Condition:
|
Completed |
Study Name: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition:
|
Completed |
Study Name: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) Condition:
|
Completed |
Study Name: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients Condition:
|
Completed |
Study Name: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Condition:
Date: 2010-01-07 Interventions: Drug: rilonacept 160mg of rilonacept 1x/week Other N |
Recruiting |
Study Name: Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) Condition:
|